Search

Emmanuel Y Normant

from New York, NY
Age ~60
Get Report
Also known as:
Emmanuel S Normant, Emanuel S Normant
Phone and address:
677 W End Ave APT 16A, New York, NY 10025
(781) 721-1598
Related to:
Tibo Normant
Connected to:
Benjamin B Normark, 61Diana Normatov, 42Stanislav Normatov, 40Arthur P Norment, 69Eli Norment, 35Jakob L Norment, 41Stephanie K Norment, 81Susan A Norment, 57Tonya D Norment, 54Darnell Normil, 32

Emmanuel Normant Phones & Addresses

  • 677 W End Ave APT 16A, New York, NY 10025 (781) 721-1598
  • Arlington, MA
  • 104 Sylvester Ave, Winchester, MA 01890 (781) 721-1598
  • 1601 Jefferson St, Rockville, MD 20852

Work

Company: Tg therapeutics, inc. 2017 Position: Vice president, preclinical sciences

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Sorbonne Université 1990 to 1995 Specialities: Molecular Biology

Skills

Drug Discovery • Assay Development • Cell Biology • Biotechnology • Biomarkers • Pharmaceutical Industry • Oncology • Pharmacology • Clinical Development • Translational Medicine • Drug Development • Cell • In Vivo • Immunology • Lifesciences • Ind • Cro • Inflammation • Molecular Biology • Lead Change • Life Sciences • Clinical Trials • Biochemistry • Target Identification • Validation • Pharmacokinetics • High Throughput Screening • In Vitro • Organic Chemistry • Drug Design • Medicinal Chemistry

Languages

French • English

Industries

Biotechnology

Resumes

Resumes

Emmanuel Normant Photo 1

Vice President, Preclinical Sciences

View page
Location:
New York, NY
Industry:
Biotechnology
Work:
Tg Therapeutics, Inc.
Vice President, Preclinical Sciences
Surface Oncology Inc. 2015 - 2017
Director, Pharmacology
Constellation Pharmaceuticals 2011 - 2015
Director Pharmacology
Ipi 2002 - 2011
Associate Director, Cancer Biology
Pfizer 1998 - 2002
Senior Scientist
Education:
Sorbonne Université 1990 - 1995
Doctorates, Doctor of Philosophy, Molecular Biology Paris - Sud University (Paris Xi) 1983 - 1989
Doctorates, Doctor of Pharmacy, Pharmacy
Skills:
Drug Discovery
Assay Development
Cell Biology
Biotechnology
Biomarkers
Pharmaceutical Industry
Oncology
Pharmacology
Clinical Development
Translational Medicine
Drug Development
Cell
In Vivo
Immunology
Lifesciences
Ind
Cro
Inflammation
Molecular Biology
Lead Change
Life Sciences
Clinical Trials
Biochemistry
Target Identification
Validation
Pharmacokinetics
High Throughput Screening
In Vitro
Organic Chemistry
Drug Design
Medicinal Chemistry
Languages:
French
English

Publications

Us Patents

Compositions, Kits, And Methods For Identification, Assessment, Prevention, And Therapy Of Cancer

View page
US Patent:
20110118298, May 19, 2011
Filed:
Nov 12, 2010
Appl. No.:
12/945809
Inventors:
Christian Fritz - Natick MA, US
Emmanuel Y. Normant - Winchester MA, US
Juan Guillermo Paez - Spencer MA, US
Kip A. West - Nahant MA, US
Assignee:
INFINITY PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
A61K 31/395
C12Q 1/68
G01N 33/53
G01N 33/573
A61K 31/436
A61P 35/00
A61P 35/02
US Classification:
514291, 435 6, 435 71, 435 74, 514183
Abstract:
Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) are likely to respond to treatment with an HSP90 inhibitor, as a single agent or in combination therapy. Further described are methods for prognosing a time course of disease in a subject having such cancer.

Modified Par Receptors, Their Preparation And Their Uses For Selecting Compounds Which Modulate Par Activity

View page
US Patent:
20040082773, Apr 29, 2004
Filed:
Jun 27, 2003
Appl. No.:
10/609831
Inventors:
Claire Berthelier - Villebon sur Yvette, FR
Claire Bigogne - Sainte Genevieve des Bois, FR
Stephane Milano - Le Bourg, FR
Emmanuel Normant - Winchester MA, US
Assignee:
Pfizer Inc.
International Classification:
C07K014/705
C07H021/04
US Classification:
536/023500, 530/350000, 435/069100, 435/320100, 435/325000
Abstract:
The invention describes novel PAR polypeptides and uses thereof. It relates in particular to PAR polypeptides lacking their functional endogenous activating peptide and capable of interacting constitutively with a ligand for a wild-type PAR. The invention also lies in methods of screening for active compounds, using modified PAR polypeptides, and also in the therapeutic use of identified compounds, in particular for the treatment of inflammation, of allergies, of diseases affecting the CNS, of neurodegeneration, or of psychiatric or cardiovascular diseases, and also in methods and compositions which can be used for this purpose. Other subjects of the invention include nucleic acids encoding a modified PAR, vectors and recombinant host cells and transgenic animals containing them, and also their uses in the context of a therapeutic, diagnostic or screening approach, for example.
Control profile
Emmanuel Y Normant from New York, NY, age ~60 Get Report